
Alzheimer’s Disease Drugs
Description
Global Alzheimer’s Disease Drugs Market to Reach US$12.3 Billion by 2030
The global market for Alzheimer’s Disease Drugs estimated at US$8.9 Billion in the year 2024, is expected to reach US$12.3 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Donepezil, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$5.2 Billion by the end of the analysis period. Growth in the Memantine segment is estimated at 6.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.5% CAGR
The Alzheimer’s Disease Drugs market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.
Global Alzheimer’s Disease Drugs Market - Key Trends and Drivers Summarized
Why Are Alzheimer’s Disease Drugs So Crucial in Modern Medicine?
Alzheimer’s disease drugs are vital in the battle against one of the most challenging neurodegenerative conditions that affect millions of people worldwide. Alzheimer’s disease is the most common cause of dementia, characterized by a gradual decline in memory, cognitive abilities, and behavioral functions. As the disease progresses, individuals lose the ability to perform even basic daily tasks, leading to a heavy burden on both patients and caregivers. While there is no cure for Alzheimer’s disease, current medications focus on managing symptoms, slowing the progression of cognitive decline, and improving the quality of life for patients. These drugs are designed to target the neurotransmitter imbalances and neural damage that are hallmarks of the disease, particularly the build-up of amyloid plaques and tau protein tangles in the brain. By addressing these pathological factors, Alzheimer’s disease drugs aim to stabilize cognitive function and reduce symptoms such as confusion, memory loss, and agitation. The role these drugs play in managing a disease that has such a profound impact on aging populations and healthcare systems makes them essential in the field of neurology and geriatric care.
How Do Alzheimer’s Disease Drugs Work to Manage Symptoms?
Alzheimer’s disease drugs are classified into two primary categories based on their mechanisms of action: cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, work by increasing the levels of acetylcholine, a neurotransmitter crucial for memory and learning. In Alzheimer’s patients, the levels of acetylcholine in the brain are significantly reduced due to the damage to cholinergic neurons. By inhibiting the enzyme that breaks down acetylcholine, these drugs help improve communication between nerve cells, thereby temporarily enhancing cognitive function and alleviating some of the symptoms related to memory and learning. These drugs are primarily used in the early to moderate stages of the disease, where they can help slow cognitive decline and support daily functioning. NMDA (N-methyl-D-aspartate) receptor antagonists, such as memantine, are used for more moderate to severe cases of Alzheimer’s. These drugs target the brain’s glutamatergic system, specifically regulating the activity of glutamate, a neurotransmitter involved in learning and memory. In Alzheimer’s disease, excess glutamate overstimulates NMDA receptors, leading to neuronal damage and worsening cognitive function. Memantine helps block excessive stimulation of NMDA receptors, reducing excitotoxicity and helping to preserve neurons. Some treatment plans combine both cholinesterase inhibitors and NMDA receptor antagonists to provide a more comprehensive approach, addressing different pathways involved in Alzheimer’s progression. Though these drugs do not stop the underlying causes of Alzheimer’s disease, they offer critical relief by managing symptoms, helping patients maintain independence for as long as possible.
What Are the Challenges and Advances in Alzheimer’s Disease Drug Development?
The development of Alzheimer’s disease drugs has faced considerable challenges, largely due to the complexity of the disease’s pathology and the difficulty of delivering effective treatments to the brain. Alzheimer’s is marked by the accumulation of beta-amyloid plaques and tau tangles, both of which contribute to the death of neurons and the deterioration of cognitive function. Despite decades of research, targeting these proteins has proven difficult, as many potential drugs have failed to show significant benefits in clinical trials. The blood-brain barrier, a protective layer that prevents most substances from entering the brain, further complicates drug delivery, making it challenging for treatments to reach the affected areas of the brain. However, there have been recent breakthroughs in drug development, particularly with the introduction of disease-modifying therapies that aim to target the underlying causes of Alzheimer’s rather than just managing symptoms. One of the most significant advancements is the approval of monoclonal antibodies like aducanumab, which is designed to reduce amyloid plaque build-up in the brain. This drug represents a shift in the treatment paradigm, offering the possibility of slowing disease progression rather than merely alleviating symptoms. Researchers are also exploring tau-based therapies, gene therapies, and neuroprotective agents that aim to intervene earlier in the disease process and protect neurons from further damage. While these approaches are still in the early stages of development, they offer hope for more effective treatments in the future.
What Is Driving the Growth in the Alzheimer’s Disease Drugs Market?
The growth in the Alzheimer’s disease drugs market is driven by several key factors, all of which are linked to the rising global prevalence of the disease, advances in drug development, and increased investment in research. One of the primary drivers is the rapid increase in the aging population worldwide, particularly in developed nations where life expectancy continues to rise. Alzheimer’s disease is strongly associated with aging, and as the number of elderly individuals grows, so too does the incidence of Alzheimer’s, creating a greater demand for effective treatments. As awareness of Alzheimer’s disease and dementia-related disorders continues to increase, more people are seeking early diagnosis and treatment, leading to greater uptake of available medications. Another significant growth driver is the advancement in biotechnology and pharmaceutical research, which has led to new classes of drugs that target the disease more directly. The approval of novel treatments such as monoclonal antibodies that target beta-amyloid has provided new hope for slowing the progression of Alzheimer’s, sparking renewed interest in disease-modifying therapies. Additionally, the substantial investment in Alzheimer’s research from both government and private sectors is fueling the discovery of new potential therapies. The expansion of clinical trials and the introduction of more targeted, personalized treatments are also propelling market growth. As researchers better understand the genetic and environmental factors that contribute to Alzheimer’s, there is a growing interest in developing therapies tailored to individual patients’ genetic profiles or specific biomarkers, further enhancing treatment efficacy. Furthermore, the rising healthcare expenditure and improving diagnostic technologies are allowing for earlier detection and intervention, which increases the need for drugs that can slow disease progression from the onset. Together, these factors are driving a significant expansion in the Alzheimer’s disease drugs market.
SCOPE OF STUDY:The report analyzes the Alzheimer’s Disease Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Donepezil, Memantine, Galantamine, Rivastigmine, Other Drug Classes)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
- Allergen
- Biogen
- Daiichi Sankyo Company Limited
- Eisai Co Ltd
- Eli Lilly
- Genentech
- H Lundbeck A/S
- Johnson & Johnson
- Lundbeck
- Merck
- Merz Holding GmbH & Co KG
- Novartis
- Ono Pharmaceutica
- Pfizer
- Roche
- Takeda
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Alzheimer’s Disease Drugs – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Alzheimer`s Disease Propels Growth in Demand for Alzheimer`s Disease Drugs
- Increasing Aging Population Expands Addressable Market for Alzheimer`s Treatments
- Advancements in Disease-Modifying Therapies Drive Innovation in Alzheimer`s Drug Development
- Focus on Early Diagnosis and Intervention Strengthens the Business Case for Alzheimer`s Medications
- Shift Towards Personalized Medicine Spurs Demand for Targeted Alzheimer`s Disease Drugs
- Here`s How Increasing Use of Biomarkers in Clinical Trials Drives Growth in Alzheimer`s Drug Discovery
- Growing Awareness of Cognitive Health Generates Demand for Preventive Alzheimer`s Medications
- Surging Interest in Combination Therapies Strengthens the Case for Multi-Targeted Alzheimer`s Disease Drugs
- Here`s How Advancements in Blood-Brain Barrier Penetration Technologies Propel Innovation in Alzheimer`s Treatments
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 2: World Historic Review for Alzheimer’s Disease Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 3: World 15-Year Perspective for Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Memantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 5: World Historic Review for Memantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 6: World 15-Year Perspective for Memantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 7: World Alzheimer’s Disease Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Donepezil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Donepezil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Donepezil by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Galantamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Galantamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Galantamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Rivastigmine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Rivastigmine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Rivastigmine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- I
- II. MARKET ANALYSIS
- UNITED STATES
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: USA 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- CANADA
- TABLE 23: Canada Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: Canada Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: Canada 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- JAPAN
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 26: Japan Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Japan Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: Japan 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- CHINA
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 29: China Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: China Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: China 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- EUROPE
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 32: Europe Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Alzheimer’s Disease Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: Europe 15-Year Perspective for Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 35: Europe Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Europe Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Europe 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- FRANCE
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 38: France Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: France Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: France 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- GERMANY
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 41: Germany Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Germany Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Germany 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- ITALY
- TABLE 44: Italy Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Italy Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Italy 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 47: UK Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: UK Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: UK 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 50: Spain Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Spain Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Spain 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 53: Russia Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Russia Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Russia 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Rest of Europe Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Rest of Europe 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 60: Asia-Pacific Historic Review for Alzheimer’s Disease Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Asia-Pacific 15-Year Perspective for Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Asia-Pacific Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Asia-Pacific 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- AUSTRALIA
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 65: Australia Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Australia Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Australia 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- INDIA
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 68: India Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: India Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: India 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 71: South Korea Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: South Korea Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: South Korea 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Rest of Asia-Pacific Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 77: Latin America Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 78: Latin America Historic Review for Alzheimer’s Disease Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Latin America 15-Year Perspective for Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 80: Latin America Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Latin America Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Latin America 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 83: Argentina Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Argentina Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Argentina 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 86: Brazil Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Brazil Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Brazil 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 89: Mexico Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Mexico Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Mexico 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Rest of Latin America Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Rest of Latin America 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 95: Middle East Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 96: Middle East Historic Review for Alzheimer’s Disease Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Middle East 15-Year Perspective for Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 98: Middle East Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Middle East Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Middle East 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- IRAN
- TABLE 101: Iran Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Iran Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Iran 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 104: Israel Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Israel Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Israel 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Saudi Arabia Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Saudi Arabia 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 110: UAE Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: UAE Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: UAE 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Rest of Middle East Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Rest of Middle East 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- AFRICA
- Alzheimer’s Disease Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 116: Africa Recent Past, Current & Future Analysis for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Africa Historic Review for Alzheimer’s Disease Drugs by Drug Class - Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Africa 15-Year Perspective for Alzheimer’s Disease Drugs by Drug Class - Percentage Breakdown of Value Sales for Donepezil, Memantine, Galantamine, Rivastigmine and Other Drug Classes for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates